RAPTOR:戊酮可可碱-生育酚-氯膦酸盐治疗下颌骨放射性骨坏死的随机对照试验——开放标签II期随机对照优效性试验研究方案
下颌骨放射性骨坏死(ORN)是头颈恶性肿瘤放疗后严重晚期毒性,发生率5-10%,缺乏稳健医学证据。RAPTOR为II期开放标签多中心随机对照优效性试验,将下颌骨ORN患者1:1随机分配至标准治疗(A组)或PENTOCLO联合标准治疗(B组)12个月,主要结局为随机化至ORN愈合(无需手术)时间,并嵌入转化样本采集与电子患者报告结局(ePROM)方法学研究。
要点
- RAPTOR是首个在该临床情境下评估PENTOCLO的随机对照临床试验。
- 主要结局为随机化至ORN愈合(无需手术)时间,通过临床检查、口内照片和影像评估。
- II期结果将提供疗效初步证据,并为其后确证性试验的可行性和适当性提供信息。
核心结论
- RAPTOR是首个在该临床情境下评估PENTOCLO的随机对照临床试验,II期结果将提供其疗效的稳健初步证据,并为其后确证性试验的可行性和适当性提供信息。
研究设计与样本
- RAPTOR为II期、开放标签、多中心、随机对照优效性试验,合格下颌骨ORN受试者按1:1随机分配至标准治疗(A组)或PENTOCLO联合标准治疗(B组)12个月。
- 试验嵌入转化样本采集,并包含探索电子患者报告结局(ePROM)使用的方法学组分。
主要发现
- 原文未报告结果。
关键数值与推荐
- 主要结局指标为随机化至ORN愈合(无需手术)的时间,通过临床检查(确认口腔黏膜完全愈合)、口内临床照片和影像评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mandibular osteoradionecrosis (ORN) is a severe late radiation toxicity affecting 5-10% of patients who receive radiotherapy as part of treatment for head and neck malignancy. ORN can cause permanent disfigurement, dysfunction, pain and infection. There remains little robust evidence supporting the efficacy of medical or surgical management currently offered in clinical practice. Retrospective case series and meta-analyses of observational studies suggest that a repurposed triple drug combination pentoxifylline-tocopherol-clodronate ('PENTOCLO') may be effective in preventing deterioration, promoting healing and ultimately reducing the need for major reconstructive surgery. METHODS: The RAPTOR trial is a phase II, open-label, multicentre, randomised controlled trial with a superiority design. Eligible subjects with mandibular ORN are randomised 1:1 to receive standard of care (Arm A) or PENTOCLO plus standard of care (Arm B) for 12 months. The primary outcome measure is time from randomisation to healing of ORN (without the need for surgery), as measured by clinical examination (confirming completely healed oral mucosa), intra-oral clinical photographs and imaging. RAPTOR has an embedded translational sample collection and a methodological component exploring the use of electronic patient-reported outcome measures (ePROM). DISCUSSION: The RAPTOR trial is the first randomised controlled clinical trial of PENTOCLO in this clinical setting. The results of this phase II trial will provide robust preliminary evidence on its efficacy and inform the feasibility and appropriateness of a subsequent definitive trial. TRIAL REGISTRATION: RAPTOR is registered with the ISRCTN registry effective date 11th November 2022: Clinical trial of the non-surgical management of radiotherapy damage to the lower jaw ISRCTN34217298, and also registered with the European Clinical Trials Database (Eudra-CT 2022-000728-39).
引用
- Shaw R, Knight R, Basoglu A, et al. RAPTOR: Randomised Controlled Trial of PENTOCLO (pentoxifylline-tocopherol-clodronate) in Mandibular Osteoradionecrosis-study protocol for an open-label phase II randomised controlled superiority trial. Trials. 2025. PMID: 40708048. doi:10.1186/s13063-025-08966-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。